Key result
Diminazene aceturate treatment reduced diabetes-induced renal damage, fibrosis, and apoptosis in a rat model of type 1 diabetes, effects that were blocked by an AT2 receptor antagonist.
Why the study?
Does diminazene aceturate prevent renal damage in a rat model of type 1 diabetes?
Does diminazene aceturate prevent renal damage in a rat model of type 1 diabetes?
In a rat model of type 1 diabetes, the ACE2 activator diminazene aceturate protected against diabetic nephropathy via the ACE2/angiotensin-(1-7)/AT2 receptor axis.
Answers are grounded in this paper and cite their sources.
DIZE may attenuate diabetic nephropathy in preclinical models; leaves open clinical translation of ACE2 activation.
Background and Purpose One of the protective actions of angiotensin converting enzyme‐2 (ACE2) is the inactivation of angiotensin II. Expression and activity of ACE2 was reduced in glomeruli of diabetic patients and in animal models of diabetes. Recently the potential role of recombinant ACE2 administration in preventing diabetic nephropathy (DN) has been shown. Here we have tested the effects of the ACE2 activator, diminazene aceturate (DIZE), in a model of DN. Experimental Approach Male Wistar rats were rendered diabetic using a single dose of streptozotocin (55 mg·kg −1 , i.p.). After 4 weeks, diabetic animals were divided into experimental groups and treated with DIZE, at a low dose (5 mg·kg −1 ·day −1 ), a high dose (15 mg·kg −1 ·day −1 ) and the high dose with of the AT 2 receptor antagonist PD123319 (10 mg·kg −1 ·day −1 ). At the end of the treatment , kidneys from all the groups were collected and processed separately for glomerular isolation, protein isolation, mRNA extraction and for immunohistochemical studies. Key Results Treatment with DIZE restored ACE2 expression in glomeruli and increased expression of AT 2 receptors in whole kidney and isolated glomeruli of diabetic animals. DIZE administration reduced angiotensin II levels and increased angiotensin‐(1–7) levels in diabetic kidney. However, PD123319 treatment reversed all these actions of DIZE. Conclusions and Implications DIZE treatment reduced diabetes‐induced renal damage as shown by reduction of fibrosis and apoptosis. These protective actions of DIZE were blocked by the AT 2 receptor antagonist. Taken together, these results suggest that DIZE protected against DN through the ACE2/angiotensin‐(1–7)/ AT 2 receptor axis.
No takes yet. Share an insight, caveat, or question.
Goru et al. (2017) studied Diabetic nephropathy (type 1 diabetes). Diminazene aceturate (DIZE) vs. Diabetic control / PD123319 co-treatment was evaluated on Renal damage (fibrosis and apoptosis), ACE2 and AT2 receptor expression. Diminazene aceturate treatment reduced diabetes-induced renal damage, fibrosis, and apoptosis in a rat model of type 1 diabetes, effects that were blocked by an AT2 receptor antagonist.
Synapse has enriched 10 related papers. Consider them for comparative context: